Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.62 |
| ▸ | RXRA | P19793 | 1/20 | 0.55 |
| ▸ | RXRB | P28702 | 1/20 | 0.55 |
| ▸ | RXRG | P48443 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | FABP3 | P05413 | 1/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | RBP4 | P02753 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13506596 | 0.92 | LMNA (0.58) | FFAR4RXRARXRBRXRGMEN1 | |
| SCHEMBL6362758 | 0.84 | LMNA (0.53) | FFAR4RXRARXRBRXRGMEN1 | |
| SCHEMBL30680095 | 0.81 | RXRA (0.59) | RXRARXRBRXRGMRGPRX4PPARG | |
| SCHEMBL1577431 | 0.81 | RXRA (0.59) | RXRARXRBRXRGMRGPRX4PPARG | |
| SCHEMBL1116787 | 0.81 | RXRA (0.51) | FFAR4RXRARXRBRXRGMEN1 | |
| SCHEMBL2097943 | 0.80 | RXRA (0.49) | FFAR4RXRARXRBRXRGMEN1 | |
| SCHEMBL2097938 | 0.80 | RXRA (0.49) | RXRARXRBRXRGMEN1KMT2A | |
| SCHEMBL18833336 | 0.79 | RXRA (0.47) | RXRARXRBRXRGMEN1KMT2A | |
| SCHEMBL22778023 | 0.78 | ALDH1A1 (0.52) | RXRARXRBRXRGMEN1KMT2A | |
| SCHEMBL28550531 | 0.78 | KDM4E (0.59) | FFAR4KMT2ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306102-A1 | NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME | KOWA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306102-A1 | NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME | HSD11B1, HSD11B2, HSD3B1 | FFAR4 239/4885RXRA 2699/4885RXRB 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.